The ATTRACTION-4 trial, which evaluated nivolumab in combination with chemotherapy in untreated, HER2-negative advanced gastric cancer, showed an extension in PFS; however, subgroup analysis indicated no efficacy in patients with peritoneal metastases [9]. Here, ERBB2 is linked to gastric cancer.